Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael J. Morrison is active.

Publication


Featured researches published by Michael J. Morrison.


Journal of Medicinal Chemistry | 2008

Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.

Daniel S. La; Julie Belzile; James Bready; Angela Coxon; Thomas DeMelfi; Nicholas Doerr; Juan Estrada; Julie Flynn; Shaun Flynn; Russell Graceffa; Shawn P. Harriman; Jay Larrow; Alexander M. Long; Matthew W. Martin; Michael J. Morrison; Vinod F. Patel; Philip Roveto; Ling Wang; Matthew Weiss; Douglas A. Whittington; Yohannes Teffera; Zhiyang Zhao; Anthony Polverino; Jean-Christophe Harmange

Angiogenesis is vital for solid tumor growth, and its prevention is a proven strategy for the treatment of disease states such as cancer. The vascular endothelial growth factor (VEGF) pathway provides several opportunities by which small molecules can act as inhibitors of endothelial proliferation and migration. Critical to these processes is signaling through VEGFR-2 or the kinase insert domain receptor (KDR) upon stimulation by its ligand VEGF. Herein, we report the discovery of 2,3-dihydro-1,4-benzoxazines as inhibitors of intrinsic KDR activity (IC 50 < 0.1 microM) and human umbilical vein endothelial cell (HUVEC) proliferation with IC 50 < 0.1 microM. More specifically, compound 16 was identified as a potent (KDR: < 1 nM and HUVEC: 4 nM) and selective inhibitor that exhibited efficacy in angiogenic in vivo models. In addition, this series of molecules is typically well-absorbed orally, further demonstrating the 2,3-dihydro-1,4-benzoxazine moiety as a promising platform for generating kinase-based antiangiogenic therapeutic agents.


Biochemistry | 2014

The Renaissance of Bacillosamine and Its Derivatives: Pathway Characterization and Implications in Pathogenicity

Michael J. Morrison; Barbara Imperiali

Prokaryote-specific sugars, including N,N′-diacetylbacillosamine (diNAcBac) and pseudaminic acid, have experienced a renaissance in the past decade because of their discovery in glycans related to microbial pathogenicity. DiNAcBac is found at the reducing end of oligosaccharides of N- and O-linked bacterial protein glycosylation pathways of Gram-negative pathogens, including Campylobacter jejuni and Neisseria gonorrhoeae. Further derivatization of diNAcBac results in the nonulosonic acid known as legionaminic acid, which was first characterized in the O-antigen of the lipopolysaccharide (LPS) in Legionella pneumophila. Pseudaminic acid, an isomer of legionaminic acid, is also important in pathogenic bacteria such as Helicobacter pylori because of its occurrence in O-linked glycosylation of flagellin proteins, which plays an important role in flagellar assembly and motility. Here, we present recent advances in the characterization of the biosynthetic pathways leading to these highly modified sugars and investigation of the roles that each plays in bacterial fitness and pathogenicity.


Journal of Biological Chemistry | 2013

Biochemical analysis and structure determination of bacterial acetyltransferases responsible for the biosynthesis of UDP-N,N′-diacetylbacillosamine

Michael J. Morrison; Barbara Imperiali

Background: A connection between glycoproteins containing N,N′-diacetylbacillosamine and pathogenicity has previously been shown in Campylobacter jejuni. Results: Structural and kinetic studies of two bacterial acetyltransferases show the diversity within the binding pockets responsible for UDP-N,N′-diacetylbacillosamine production. Conclusion: Carbohydrate acetyltransferases from O-linked glycosylation pathways exhibit significant divergence from their N-linked counterparts. Significance: Acetyltransferase characterization increases our understanding of the diverse nature of bacterial glycosylation. UDP-N,N′-diacetylbacillosamine (UDP-diNAcBac) is a unique carbohydrate produced by a number of bacterial species and has been implicated in pathogenesis. The terminal step in the formation of this important bacterial sugar is catalyzed by an acetyl-CoA (AcCoA)-dependent acetyltransferase in both N- and O-linked protein glycosylation pathways. This bacterial acetyltransferase is a member of the left-handed β-helix family and forms a homotrimer as the functional unit. Whereas previous endeavors have focused on the Campylobacter jejuni acetyltransferase (PglD) from the N-linked glycosylation pathway, structural characterization of the homologous enzymes in the O-linked glycosylation pathways is lacking. Herein, we present the apo-crystal structures of the acetyltransferase domain (ATD) from the bifunctional enzyme PglB (Neisseria gonorrhoeae) and the full-length acetyltransferase WeeI (Acinetobacter baumannii). Additionally, a PglB-ATD structure was solved in complex with AcCoA. Surprisingly, this structure reveals a contrasting binding mechanism for this substrate when compared with the AcCoA-bound PglD structure. A comparison between these findings and the previously solved PglD crystal structures illustrates a dichotomy among N- and O-linked glycosylation pathway enzymes. Based upon these structures, key residues in the UDP-4-amino and AcCoA binding pockets were mutated to determine their effect on binding and catalysis in PglD, PglB-ATD, and WeeI. Last, a phylogenetic analysis of the aforementioned acetyltransferases was employed to illuminate the diversity among N- and O-linked glycosylation pathway enzymes.


Journal of Medicinal Chemistry | 2017

Targeting Bacillosamine Biosynthesis in Bacterial Pathogens: Development of Inhibitors to a Bacterial Amino-Sugar Acetyltransferase from Campylobacter jejuni

Joris W. De Schutter; James P. Morrison; Michael J. Morrison; Alessio Ciulli; Barbara Imperiali

The glycoproteins of selected microbial pathogens often include highly modified carbohydrates such as 2,4-diacetamidobacillosamine (diNAcBac). These glycoconjugates are involved in host-cell interactions and may be associated with the virulence of medically significant Gram-negative bacteria. In light of genetic studies demonstrating the attenuated virulence of bacterial strains in which modified carbohydrate biosynthesis enzymes have been knocked out, we are developing small molecule inhibitors of selected enzymes as tools to evaluate whether such compounds modulate virulence. We performed fragment-based and high-throughput screens against an amino-sugar acetyltransferase enzyme, PglD, involved in biosynthesis of UDP-diNAcBac in Campylobacter jejuni. Herein we report optimization of the hits into potent small molecule inhibitors (IC50 < 300 nM). Biophysical characterization shows that the best inhibitors are competitive with acetyl coenzyme A and an X-ray cocrystal structure reveals that binding is biased toward occupation of the adenine subpocket of the AcCoA binding site by an aromatic ring.


Journal of Medicinal Chemistry | 2007

Evolution of a Highly Selective and Potent 2-(Pyridin-2-yl)-1,3,5-triazine Tie-2 Kinase Inhibitor

Brian L. Hodous; Stephanie Geuns-Meyer; Paul E. Hughes; Brian K. Albrecht; Steve Bellon; James Bready; Sean Caenepeel; Victor J. Cee; Stuart C. Chaffee; Angela Coxon; Maurice Emery; Jenne Fretland; Paul Gallant; Yan Gu; Doug Hoffman; Rebecca E. Johnson; Richard Kendall; Joseph L. Kim; Alexander M. Long; Michael J. Morrison; Philip R. Olivieri; Vinod F. Patel; Anthony Polverino; Paul Rose; Paul Tempest; Ling Wang; Douglas A. Whittington; Huilin Zhao


Biochemistry | 2011

Biochemical characterization of the O-linked glycosylation pathway in Neisseria gonorrhoeae responsible for biosynthesis of protein glycans containing N,N'-diacetylbacillosamine.

Meredith D. Hartley; Michael J. Morrison; Finn Erik Aas; Bente Børud; Michael Koomey; Barbara Imperiali


Journal of Medicinal Chemistry | 2006

Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity.

Matthew W. Martin; John Newcomb; Joseph J. Nunes; David C. Mcgowan; David M. Armistead; Christina Boucher; John L. Buchanan; William H. Buckner; Lilly Chai; Daniel Elbaum; Linda F. Epstein; Theodore Faust; Shaun Flynn; Paul Gallant; Anu Gore; Yan Gu; Faye Hsieh; Xin Huang; Josie H. Lee; Daniela Metz; Scot Middleton; Deanna Mohn; Kurt Morgenstern; Michael J. Morrison; Perry M. Novak; Antonio Oliveira-dos-Santos; David Powers; Paul Rose; Stephen Schneider; Stephanie Sell


Journal of Medicinal Chemistry | 2007

Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase.

Victor J. Cee; Brian K. Albrecht; Stephanie Geuns-Meyer; Paul E. Hughes; Steve Bellon; James Bready; Sean Caenepeel; Stuart C. Chaffee; Angela Coxon; Maurice Emery; Jenne Fretland; Paul Gallant; Yan Gu; Brian L. Hodous; Doug Hoffman; Rebecca E. Johnson; Richard Kendall; Joseph L. Kim; Alexander M. Long; David C. Mcgowan; Michael J. Morrison; Philip R. Olivieri; Vinod F. Patel; Anthony Polverino; David Powers; Paul Rose; Ling Wang; Huilin Zhao


Archives of Biochemistry and Biophysics | 2013

Biosynthesis of UDP-N,N′-diacetylbacillosamine in Acinetobacter baumannii: Biochemical characterization and correlation to existing pathways

Michael J. Morrison; Barbara Imperiali


PMC | 2011

Biochemical Characterization of the O-Linked Glycosylation Pathway in Neisseria gonorrhoeae Responsible for Biosynthesis of Protein Glycans Containing N,N '-Diacetylbacillosamine

Meredith D. Hartley; Michael J. Morrison; Barbara Imperiali; Finn Erik Aas; Bente Børud; Michael Koomey

Collaboration


Dive into the Michael J. Morrison's collaboration.

Researchain Logo
Decentralizing Knowledge